MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$53,458K
EPS
-$0.3
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and development
38,598 59,994* 40,520 -
General and administrative
14,266 23,551* 12,180 -
Acquired in-process research and development
--10,000* 5,000 -
Total operating expenses
52,864 73,545 57,700 -
Loss from operations
-52,864 -73,545* -57,700 -54,040
Interest income
1,231 1,976* 1,685 -
Interest expense
1,854 978* 747 -
Other income (expense), net
59 -57* 7 -480
Interest income, net
---1,814
Total other income (expense)
-564 940* 945 1,334
Net loss before income taxes
-53,428 -72,606* -56,755 -52,706
Provision for income taxes
30 93* 0 25
Net loss
-53,458 -72,699* -56,755 -52,731
Unrealized loss on marketable debt securities
0 -80* 24 -12
Comprehensive loss
-53,458 -72,779 -56,731 -52,743
Basic EPS
-0.3 -0.437 -0.35 -0.33
Diluted EPS
-0.3 -0.437 -0.35 -0.33
Basic Average Shares
179,872,000 166,644,000 161,838,000 161,691,000
Diluted Average Shares
179,872,000 166,644,000 161,838,000 161,691,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$53,458K Net loss-$53,458K Net loss beforeincome taxes-$53,428K Provision for income taxes$30K Loss from operations-$52,864K Total other income(expense)-$564K Interest income$1,231K Other income(expense), net$59K Total operatingexpenses$52,864K Interest expense$1,854K Research and development$38,598K General andadministrative$14,266K

Neumora Therapeutics, Inc. (NMRA)

Neumora Therapeutics, Inc. (NMRA)